Yoon-Soo Bae, MD
Dermatology · New York, NYNPI 1023251014
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,085 of the $34,057 with a category attached, or 70.7%. AbbVie accounts for 87.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $15,652 and has fallen 99.7% since, to $54 in 2025.
Across 43 payments — averaging $792.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$30K
- Galderma Laboratories, L.p.$4K
- Arcutis Biotherapeutics, Inc.$50
- Amgen$21
- Pfizer$16
Across 4 payments — averaging $381.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
What the payments were for
- Consulting fees$24,08571%
- Speaking & faculty fees$6,90020%
- Travel & lodging$1,8595%
- Food & beverage$1,2134%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $29,944 |
| Galderma Laboratories, L.p. | 4 | $4,026 |
| Arcutis Biotherapeutics, Inc. | 2 | $50 |
| Amgen | 1 | $21 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$442
How this compares
$34,057 in reported general payments places this provider in the 85th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 67 | $3,853 |
| Doxycycline Hyclate | 23 | $422 |
| Ketoconazole | 16 | $305 |
| ValacyclovirValacyclovir Hcl | 11 | $170 |
| Triamcinolone Acetonide | 19 | $109 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New York
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Joshua ZeichnerNew York$2.1M
- Emma GuttmanNew York$1.7M
- George HanNew York$1.6M
- Amy SpizuocoNew York$1.3M
- Andrew AlexisNew York$834K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.